A bipartisan bill in the Ohio Statehouse would ban homeowners associations and landlords from prohibiting thin blue line flags.

When Donald Trump took office, he swore to “preserve, protect and defend the Constitution.” The oath is essential, because ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

Gilead Sciences (GILD) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the ...

Medical pioneer Gilead Sciences GILD has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks. Gilead has joined Johnson & Johnson JNJ, and a cluster ...

NEW YORK, March 3 (Reuters) - Gilead Sciences (GILD.O), opens new tab set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into the drugmaker's ...

Two weeks ago, Gilead Sciences released financial results for the fourth quarter of 2024, which exceeded even my most optimistic expectations. The strong performance of its HIV franchise was ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...

Each risk assessment will analyze the data to flag sites with potential issues and provide a visualization to help the user understand the issue. Some relevant references are provided below.